Duc Ha
Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 17 | 2023 | 2206 | 4.260 |
Why?
| Cancer Survivors | 7 | 2023 | 203 | 4.120 |
Why?
| Quality of Life | 8 | 2023 | 2390 | 1.390 |
Why?
| Heart Rate | 3 | 2019 | 700 | 1.300 |
Why?
| Dyspnea | 3 | 2023 | 224 | 0.990 |
Why?
| Exercise Test | 5 | 2020 | 541 | 0.970 |
Why?
| Exercise | 5 | 2021 | 1611 | 0.910 |
Why?
| Telerehabilitation | 1 | 2023 | 26 | 0.870 |
Why?
| Exercise Tolerance | 2 | 2020 | 223 | 0.780 |
Why?
| Leisure Activities | 1 | 2021 | 24 | 0.750 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 964 | 0.700 |
Why?
| Cost-Benefit Analysis | 1 | 2020 | 548 | 0.570 |
Why?
| Chemoradiotherapy | 1 | 2018 | 187 | 0.570 |
Why?
| Pneumonectomy | 2 | 2016 | 126 | 0.570 |
Why?
| Lung | 4 | 2023 | 3683 | 0.560 |
Why?
| Exercise Therapy | 1 | 2020 | 353 | 0.540 |
Why?
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 1115 | 0.510 |
Why?
| Telemedicine | 1 | 2023 | 667 | 0.490 |
Why?
| Respiratory Tract Diseases | 1 | 2015 | 142 | 0.460 |
Why?
| Neoplasms, Second Primary | 1 | 2015 | 91 | 0.450 |
Why?
| Forecasting | 1 | 2015 | 332 | 0.440 |
Why?
| Aged | 10 | 2021 | 19292 | 0.430 |
Why?
| Electromagnetic Phenomena | 1 | 2013 | 22 | 0.430 |
Why?
| Cross-Sectional Studies | 5 | 2021 | 4447 | 0.430 |
Why?
| Veterans | 2 | 2020 | 1232 | 0.400 |
Why?
| Surveys and Questionnaires | 5 | 2022 | 4673 | 0.400 |
Why?
| Small Cell Lung Carcinoma | 1 | 2013 | 77 | 0.390 |
Why?
| Neoplasm Staging | 3 | 2021 | 1177 | 0.390 |
Why?
| Heart Diseases | 1 | 2014 | 332 | 0.380 |
Why?
| Bronchoscopy | 1 | 2013 | 245 | 0.370 |
Why?
| Humans | 21 | 2023 | 115859 | 0.320 |
Why?
| Lung Diseases | 1 | 2014 | 710 | 0.310 |
Why?
| Carcinoma, Squamous Cell | 1 | 2013 | 577 | 0.300 |
Why?
| Patient Reported Outcome Measures | 2 | 2020 | 250 | 0.280 |
Why?
| Adenocarcinoma | 1 | 2013 | 797 | 0.270 |
Why?
| Male | 11 | 2021 | 56103 | 0.260 |
Why?
| Middle Aged | 7 | 2021 | 27078 | 0.260 |
Why?
| Female | 11 | 2021 | 60070 | 0.250 |
Why?
| Prognosis | 3 | 2016 | 3344 | 0.220 |
Why?
| Survivors | 2 | 2023 | 404 | 0.220 |
Why?
| Retrospective Studies | 5 | 2021 | 12615 | 0.220 |
Why?
| Oxygen Consumption | 2 | 2016 | 572 | 0.220 |
Why?
| Logistic Models | 2 | 2021 | 1863 | 0.220 |
Why?
| Muscles | 1 | 2023 | 328 | 0.210 |
Why?
| Fatigue | 2 | 2023 | 296 | 0.200 |
Why?
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 44 | 0.190 |
Why?
| Confidence Intervals | 1 | 2021 | 309 | 0.180 |
Why?
| Sleep Wake Disorders | 1 | 2023 | 233 | 0.170 |
Why?
| Quality-Adjusted Life Years | 1 | 2020 | 103 | 0.170 |
Why?
| Markov Chains | 1 | 2020 | 115 | 0.170 |
Why?
| Walking | 1 | 2023 | 426 | 0.170 |
Why?
| Autonomic Nervous System | 1 | 2019 | 70 | 0.160 |
Why?
| Pilot Projects | 1 | 2023 | 1379 | 0.160 |
Why?
| California | 1 | 2020 | 368 | 0.160 |
Why?
| Geriatric Assessment | 1 | 2020 | 177 | 0.160 |
Why?
| Psychometrics | 1 | 2022 | 615 | 0.160 |
Why?
| Respiratory Function Tests | 1 | 2020 | 539 | 0.150 |
Why?
| Proportional Hazards Models | 1 | 2021 | 1088 | 0.150 |
Why?
| Physical Fitness | 1 | 2019 | 179 | 0.150 |
Why?
| Survivorship | 1 | 2018 | 38 | 0.150 |
Why?
| Life Style | 1 | 2020 | 428 | 0.150 |
Why?
| Time Factors | 2 | 2021 | 6182 | 0.150 |
Why?
| Time-to-Treatment | 1 | 2018 | 147 | 0.140 |
Why?
| Self Report | 1 | 2021 | 700 | 0.140 |
Why?
| Socioeconomic Factors | 1 | 2021 | 1088 | 0.140 |
Why?
| Disease-Free Survival | 1 | 2018 | 621 | 0.140 |
Why?
| Risk Assessment | 2 | 2016 | 2992 | 0.140 |
Why?
| Physical Education and Training | 1 | 2016 | 60 | 0.130 |
Why?
| Health Status | 1 | 2021 | 727 | 0.130 |
Why?
| Perioperative Period | 1 | 2015 | 49 | 0.130 |
Why?
| Autonomic Nervous System Diseases | 1 | 2015 | 27 | 0.130 |
Why?
| Parasympathetic Nervous System | 1 | 2015 | 25 | 0.130 |
Why?
| Mental Health | 1 | 2021 | 571 | 0.130 |
Why?
| Survival Analysis | 1 | 2018 | 1218 | 0.120 |
Why?
| Risk Factors | 2 | 2021 | 8715 | 0.120 |
Why?
| Ohio | 1 | 2015 | 136 | 0.120 |
Why?
| Intraoperative Complications | 1 | 2015 | 126 | 0.120 |
Why?
| Reproducibility of Results | 1 | 2022 | 2807 | 0.120 |
Why?
| Chi-Square Distribution | 1 | 2014 | 501 | 0.110 |
Why?
| Translocation, Genetic | 1 | 2013 | 94 | 0.100 |
Why?
| Kaplan-Meier Estimate | 1 | 2015 | 816 | 0.100 |
Why?
| Odds Ratio | 1 | 2014 | 968 | 0.100 |
Why?
| Microtubule-Associated Proteins | 1 | 2013 | 176 | 0.100 |
Why?
| Multivariate Analysis | 1 | 2014 | 1443 | 0.090 |
Why?
| Recovery of Function | 1 | 2014 | 576 | 0.090 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 225 | 0.090 |
Why?
| Survival Rate | 1 | 2015 | 1649 | 0.090 |
Why?
| Lung Diseases, Interstitial | 1 | 2015 | 520 | 0.090 |
Why?
| Cohort Studies | 1 | 2020 | 4960 | 0.090 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1813 | 0.090 |
Why?
| Chronic Disease | 1 | 2015 | 1598 | 0.090 |
Why?
| ErbB Receptors | 1 | 2013 | 557 | 0.080 |
Why?
| Multigene Family | 2 | 2008 | 198 | 0.080 |
Why?
| Codon, Initiator | 1 | 2009 | 7 | 0.080 |
Why?
| Peptide Chain Initiation, Translational | 1 | 2009 | 38 | 0.080 |
Why?
| Prospective Studies | 1 | 2020 | 6276 | 0.080 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 2008 | 28 | 0.080 |
Why?
| Embryonic Stem Cells | 1 | 2008 | 105 | 0.070 |
Why?
| Sequence Homology, Amino Acid | 1 | 2008 | 353 | 0.070 |
Why?
| Antigens, Neoplasm | 1 | 2008 | 224 | 0.070 |
Why?
| Neoplasm Proteins | 1 | 2009 | 388 | 0.070 |
Why?
| United States | 1 | 2021 | 12319 | 0.060 |
Why?
| Genome, Human | 1 | 2006 | 372 | 0.060 |
Why?
| Actins | 1 | 2006 | 384 | 0.060 |
Why?
| Cardiovascular Diseases | 1 | 2015 | 1724 | 0.060 |
Why?
| Recombinant Fusion Proteins | 1 | 2006 | 617 | 0.060 |
Why?
| Evolution, Molecular | 1 | 2006 | 442 | 0.050 |
Why?
| Adult | 2 | 2015 | 30814 | 0.050 |
Why?
| Aged, 80 and over | 1 | 2013 | 6434 | 0.050 |
Why?
| Treatment Outcome | 1 | 2014 | 9163 | 0.050 |
Why?
| Proteins | 1 | 2006 | 920 | 0.050 |
Why?
| Protein Isoforms | 2 | 2009 | 339 | 0.040 |
Why?
| Neoplasms | 1 | 2009 | 2114 | 0.030 |
Why?
| Molecular Sequence Data | 2 | 2008 | 2796 | 0.030 |
Why?
| Cell Line, Tumor | 2 | 2009 | 2749 | 0.020 |
Why?
| Sequence Analysis, Protein | 1 | 2009 | 29 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 139 | 0.020 |
Why?
| Testis | 1 | 2008 | 134 | 0.020 |
Why?
| Cloning, Molecular | 1 | 2008 | 523 | 0.020 |
Why?
| Azacitidine | 1 | 2008 | 130 | 0.020 |
Why?
| Chromosome Mapping | 1 | 2008 | 505 | 0.020 |
Why?
| Haplorhini | 1 | 2006 | 60 | 0.020 |
Why?
| Mutagenesis, Insertional | 1 | 2006 | 60 | 0.020 |
Why?
| Retroelements | 1 | 2006 | 39 | 0.020 |
Why?
| Cell Lineage | 1 | 2008 | 310 | 0.020 |
Why?
| Sequence Alignment | 1 | 2006 | 328 | 0.020 |
Why?
| Tissue Distribution | 1 | 2006 | 324 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2008 | 2003 | 0.010 |
Why?
| Fetus | 1 | 2008 | 703 | 0.010 |
Why?
| DNA Methylation | 1 | 2008 | 502 | 0.010 |
Why?
| Phylogeny | 1 | 2006 | 806 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2009 | 1317 | 0.010 |
Why?
| Gene Expression | 1 | 2008 | 1442 | 0.010 |
Why?
| Base Sequence | 1 | 2006 | 2121 | 0.010 |
Why?
| RNA, Messenger | 1 | 2009 | 2581 | 0.010 |
Why?
| Cell Differentiation | 1 | 2008 | 1709 | 0.010 |
Why?
| Cells, Cultured | 1 | 2008 | 3914 | 0.010 |
Why?
| Brain | 1 | 2008 | 2372 | 0.010 |
Why?
| Breast Neoplasms | 1 | 2006 | 1872 | 0.010 |
Why?
| Animals | 1 | 2006 | 32158 | 0.000 |
Why?
|
|
Ha's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|